World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
76947
World Ranking
8390
National Ranking
4339

Overview

Mario Sznol is affiliated with Yale University in the United States. Their research spans primarily the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, and Cancer Research. The body of work emphasizes cancer immunotherapy and biomarker research, CAR-T cell therapy, and immunotherapy and immune response mechanisms.

The recent publications of Mario Sznol include the following papers:

  • "T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma," 2022, Nature Medicine
  • "Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce," 2020, Journal for ImmunoTherapy of Cancer
  • "Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma," 2020, Clinical Cancer Research
  • "KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements," 2021, Nature
  • "Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab," 2023, Journal of Clinical Oncology

Mario Sznol has collaborated frequently with several co-authors, including:

  • Harriet M. Kluger
  • Michael E. Hurwitz
  • Ruth Halaban
  • Marcus Bosenberg
  • Lucia B. Jilaveanu

The scientist's work has been published extensively in journals such as:

  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Journal for ImmunoTherapy of Cancer
  • Clinical Cancer Research
  • Cancer Research

The key research topics investigated by Mario Sznol include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Cancer Genomics and Diagnostics
  • Ocular Oncology and Treatments
  • Colorectal Cancer Treatments and Studies

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

    Michael B. Atkins;Michael T. Lotze;Janice P. Dutcher;Richard I. Fisher

  • Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

    Gwendolyn Fyfe;Richard I. Fisher;Steven A. Rosenberg;Mario Sznol

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

    Michael Krauthammer;Yong Lin Kong;Byung Hak Ha;Perry Evans

  • Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

    Jeffrey S. Weber;F. Stephen Hodi;Jedd D. Wolchok;Suzanne L. Topalian

  • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

    Kim Margolin;Marc S Ernstoff;Omid Hamid;Donald Lawrence

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

    Sarah B Goldberg;Scott N Gettinger;Amit Mahajan;Anne C Chiang

  • Programmed death ligand-1 expression in non-small cell lung cancer.

    Vamsidhar Velcheti;Kurt A Schalper;Daniel E Carvajal;Valsamo K Anagnostou

  • Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

    Jun Wang;Miguel F. Sanmamed;Ila Datar;Tina Tianjiao Su

  • Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

    Mario Sznol;Lieping Chen

  • Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma

    John F. Toso;Vee J. Gill;Patrick Hwu;Francesco M. Marincola

  • Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

    Jeffrey J. Wallin;Johanna C. Bendell;Roel Funke;Mario Sznol

  • Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Sandra P D'Angelo;James Larkin;Jeffrey A Sosman;Celeste Lebbé

  • Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

    David F. McDermott;Jeffrey A. Sosman;Mario Sznol;Christophe Massard

Frequent Co-Authors

Harriet M. Kluger
Harriet M. Kluger Yale University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Michael B. Atkins
Michael B. Atkins Georgetown University
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
F. Stephen Hodi
F. Stephen Hodi Harvard University
Ruth Halaban
Ruth Halaban Yale University
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Toni K. Choueiri
Toni K. Choueiri Harvard University
Richard D. Carvajal
Richard D. Carvajal Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine offers a variety of educational pathways beyond the traditional MD. Many students are now considering online options to further their expertise or enter allied health fields. Advanced nursing students, for example, can look into best dnp programs online, which prepare graduates for leadership roles in healthcare and clinical practice.

If your interests align more with pharmaceuticals, pharm d online programs offer flexible learning for those aiming to become licensed pharmacists. These programs blend rigorous coursework with practical training, equipping graduates for dynamic roles in healthcare.

For those drawn to the intersection of technology and health, health information technology programs online can open doors to careers managing patient data and healthcare systems, a growing field in today’s digital age.

Additionally, if you’re interested in administrative roles, learning how much is medical billing and coding school could help you start a career in medical billing and coding, which is vital for healthcare operations. Each pathway offers unique opportunities and the flexibility of online learning to help launch or advance your career in medicine and health.

Best Scientists Citing Mario Sznol

Trending Scientists